1. Home
  2. AUST vs LEXX Comparison

AUST vs LEXX Comparison

Compare AUST & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Austin Gold Corp.

AUST

Austin Gold Corp.

HOLD

Current Price

$1.72

Market Cap

23.3M

Sector

N/A

ML Signal

HOLD

Logo Lexaria Bioscience Corp.

LEXX

Lexaria Bioscience Corp.

HOLD

Current Price

$0.62

Market Cap

18.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AUST
LEXX
Founded
2020
2004
Country
Canada
Canada
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
23.3M
18.9M
IPO Year
2022
N/A

Fundamental Metrics

Financial Performance
Metric
AUST
LEXX
Price
$1.72
$0.62
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$1.50
AVG Volume (30 Days)
3.9M
173.0K
Earning Date
02-26-2026
04-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$522,000.00
Revenue This Year
N/A
$13.35
Revenue Next Year
N/A
$78.83
P/E Ratio
N/A
N/A
Revenue Growth
N/A
5.05
52 Week Low
$1.05
$0.46
52 Week High
$3.92
$1.90

Technical Indicators

Market Signals
Indicator
AUST
LEXX
Relative Strength Index (RSI) 44.40 38.81
Support Level $1.65 $0.67
Resistance Level $2.15 $0.79
Average True Range (ATR) 0.35 0.07
MACD -0.05 -0.01
Stochastic Oscillator 6.04 15.69

Price Performance

Historical Comparison
AUST
LEXX

About AUST Austin Gold Corp.

Austin Gold Corp is focused on the acquisition, exploration and evaluation of mineral resource properties in the western United States of America (USA). Exploration and development of mineral projects is considered the Company's single business segment. Its projects include Kelly Creek in Humboldt County, Lone Mountain and Miller in Elko County, and Stockade Mountain (Oregon).

About LEXX Lexaria Bioscience Corp.

Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.

Share on Social Networks: